Jie Liu

Jie Liu

Managing Director

New York Office  |

Jie Liu, a Managing Director at Torreya, leads the company’s operations in China. He has over 20 years of experience in the pharmaceutical and healthcare industries, mostly focused on global licensing and M&A. In his current role, Jie is active in a variety of transactions in both branded and generic opportunities in the US and China.

Jie has done 15 transactions related to China since joining Torreya. Notable transactions include the licensing of China rights for Arbutus’ HBV product to Qilu, JV of Luoxin and Aurobindo in respiratory and licensing of Calliditas’ Tarpeyo for IgA nephropathy to Everest Medicine in the Greater China region.

Jie joined Torreya in 2016 from Heritage Pharma, a subsidiary of Emcure Pharmaceuticals, where he was Vice President, Business Development and Licensing. Previously, he was Senior Director, Global Business Development at Teva, and held business development positions with increasing responsibilities at J&J, Cephalon, and Auxilium.

Jie received a B.A. from Tianjin University in China and an M.B.A. in healthcare from the Wharton School at the University of Pennsylvania. Jie is a native Mandarin speaker.

Selected Transactions

Sesen Bio
License of Vicineum™ in Greater China Region to
Qilu Pharmaceutical
$12 million upfront
July 2020
License of Feraccru® in China to
Beijing Aosaikang Pharmaceutical
$62.8 million
January 2020
License of NOV03
in North America to
Bausch Health
December 2019
License of Gemcabene
in China to
SL Pharm
July 2019
License of Nefecon in Greater China and Singapore to
Up to $121 million
June 2019
Exclusive licensing and strategic partnership for AB-729 in China with
$55 million (upfront + equity)
+ $245 million in milestones
December 2021
Licensing of Budesolv in China to
October 2021
Bio Genuine
License agreement for GnRH antagonist Linzagolix in China from
September 2021
Sale to
$260 million
August 2021
Out -license of Bredinin™ in Mainland China to
Lee's Pharm
June 2021
License of Ravicti® in the Greater China Area, South Korea and Southeast Asia by
December 2020
License of Galinpepimut-S in Greater China by
3D Medicines
Up to $202 million with $7.5 million upfront
December 2020
JV Partnership
in China with
$50 million
December 2018
License of Durasert™ in Ophthalmology in the Greater China Region to
Ocumension Therapeutics
Up to $11.75 million
November 2018
EA Pharma
License of AJT-240 in hemodialysis in China to
Tasly Pharmaceutical Group Co., Ltd.
Up to $24 million
June 2018